Jan. 4, 2019
- Save the date for Scientific Sessions 2019We are already making plans for Scientific Sessions 2019 Nov. 16-18, 2019, in Philadelphia. Be sure to mark your calendars so you can join us to learn about all of the new science that will affect your daily work. Also, check out the dates for AHA/ASA 2019 specialty conferences. Read More
Attendees rack up steps in Walking ChallengeAttendees at Scientific Sessions 2018 tracked their daily steps and watched them feed into a leaderboard, comparing their steps to leading walkers. Read More
Let’s hackSmart Socks won the first AHA Rise Above Heart Failure Hackathon during Scientific Sessions 2018. Smart Socks and other teams of five were challenged to brainstorm a non-therapy (non-medicine) innovative solution to optimize heart patient care. Read More
HHS releases second edition of Physical Activity Guidelines for Americans: Q&A with Don Wright, MD, MPHThe U.S. Department of Health and Human Services released the second edition of the Physical Activity Guidelines for Americans.
HHS released the federal government's first science-based recommendations on physical activity to prevent disease and promote health in 2008.
Read More
Highlights of the 2018 Guideline on the Management of Blood CholesterolThe “2018 Guideline on the Management of Blood Cholesterol” is an update to the 2013 guideline on diagnosing, treating, and monitoring high cholesterol. Read More
Dec. 19, 2018
- REGROUP trial: Major adverse cardiac events results similar for endoscopic vein harvesting compared to open vein harvesting for CABGThere were no significant differences in major adverse cardiac events for endoscopic vein harvesting compared to open vein harvesting for CABG, according to Randomized Endovein Graft Prospective (REGROUP) results presented at Scientific Sessions 2018 in Chicago. Read More
- PIONEER-HF: Sacubitril/valsartan reduced cardiovascular biomarker in patients with reduced ejection fraction hospitalized for acute decompensated heart failureCompared to enalapril, sacubitril/valsartan was associated with a greater reduction in the biomarker N-terminal pro-brain natriuretic peptide and re-hospitalization for heart failure, according to a study presented at Scientific Sessions 2018 in Chicago. Read More
- BRIDGE trial suggests quality improvement interventions may increase use of evidence-based therapiesThe BRIDGE Cardiovascular Prevention Cluster Randomized Trial found that a multifaceted quality improvement educational intervention significantly increased the use of evidence-based therapies for cardiovascular disease in a low- and middle-income setting. Read More
- Results from DECLARE trials show drug may reduce CV death or hospitalizations for HF patients with Type 2 diabetesThe SGLT-2 inhibitor dapagliflozin met one primary composite endpoint with a statistically significant reduction in heart failure hospitalization or cardiovascular death versus placebo, according to results presented in a Late-Breaking Clinical Trial session at Scientific Sessions 2018 in Chicago. Read More
- Yoga may have potential for cardiac rehab in low- and middle-income settingsYoga-based cardiac rehabilitation may have potential in post-myocardial infarction patients compared with enhanced standard care, according to a multicenter randomized controlled trial in India. Read More
- REDUCE-IT finds medication added to statins reduces risks among patients with high triglyceridesPrimary results from the REDUCE-IT study found that supplemental icosapent ethyl, a prescription medication approved to reduce triglycerides ≥ 500 mg/dL, significantly reduced the risk of important cardiovascular events by 25 percent. Read More
VITAL trial considers omega-3 fatty acids, vitamin D in CV protection and cancer mortalityVITAL trial considers omega-3 fatty acids, vitamin D in CV protection and cancer mortality
Marine omega-3 fatty acids may provide a cardioprotective role, while vitamin D3 supplementation appears to benefit cancer mortality, according to principal results from the National Institutes of Health-funded VITamin D and OmegA-3 TriaL. Read More